🔗 Permalink

Inventor profile of:

Eric Furfine

City:

Concord, Massachusetts

Country:

United States

Published Applications:

Last publication date:

2025-08-14

Top Assignees for applications by Eric Furfine

The entities that hold a legal rights for patent applications filed by inventor Furfine Eric:

Regeneron Pharmaceuticals, Inc. 15 Tarrytown, NY United States
BRISTOL-MYERS SQUIBB COMPANY 9 Princeton, NJ United States
Regeneron Pharmacuticals, Inc. 1 Tarrytown, NY United States

Recent patent applications by Furfine Eric

Eric Furfine from Concord, US has applied for patents for these inventions. The list has both pending applications and granted patents:

#1 | 2025-08-14

US20250257118A1

Chemistry; metallurgy

VEGF ANTAGONIST FORMULATIONS SUITABLE FOR INTRAVITREAL ADMINISTRATION

#2 | 2025-02-06

US20250042972A1

Chemistry; metallurgy

VEGF ANTAGONIST FORMULATIONS SUITABLE FOR INTRAVITREAL ADMINISTRATION

#3 | 2023-11-23

US20230374108A1

Chemistry; metallurgy

VEGF ANTAGONIST FORMULATIONS SUITABLE FOR INTRAVITREAL ADMINISTRATION

#4 | 2021-11-04

US20210340220A1

Chemistry; metallurgy

VEGF antagonist formulations suitable for intravitreal administration

#5 | 2021-01-21

US20210017252A1

Chemistry; metallurgy

MULTIVALENT FIBRONECTIN BASED SCAFFOLD DOMAIN PROTEINS

#6 | 2020-04-30

US20200131246A1

Chemistry; metallurgy

VEGF antagonist formulations suitable for intravitreal administration

#7 | 2020-01-16

US20200017572A1

Chemistry; metallurgy

VEGF antagonist formulations suitable for intravitreal administration

#8 | 2019-07-04

US20190203248A1

Chemistry; metallurgy

Serum albumin binding molecules

#9 | 2019-01-31

US20190031735A1

Chemistry; metallurgy

VEGF antagonist formulations suitable for intravitreal administration

#10 | 2018-09-20

US20180265572A1

Chemistry; metallurgy

Method of treating cancer by administering multivalent fibronectin based scaffold domain proteins

#11 | 2018-06-07

US20180155408A1

Chemistry; metallurgy

VEGF antagonist formulations suitable for intravitreal administration

#12 | 2017-05-25

US20170145464A1

Chemistry; metallurgy

Serum albumin binding molecules

#13 | 2016-08-25

US20160244505A1

Chemistry; metallurgy

VEGF antagonist formulations suitable for intravitreal administration

#14 | 2016-07-28

US20160213608A1

Human necessities

VEGF antagonist formulations suitable for intravitreal administration

#15 | 2015-06-04

US20150152147A1

Chemistry; metallurgy

Serum albumin binding molecules

#16 | 2014-11-27

US20140349929A1

Chemistry; metallurgy

Multivalent fibronectin based scaffold domain proteins

#17 | 2014-10-30

US20140323983A1

Chemistry; metallurgy

VEGF antagonist formulations for intravitreal administration

#18 | 2013-10-17

US20130274189A1

Chemistry; metallurgy

VEGF antagonist formulations for intravitreal administration

#19 | 2013-01-10

US20130012435A1

Chemistry; metallurgy

Multivalent fibronectin based scaffold domain proteins

#20 | 2012-04-12

US20120087929A1

Chemistry; metallurgy

VEGF antagonist formulations for intravitreal administration

#21 | 2011-12-15

US20110305663A1

Chemistry; metallurgy

Serum albumin binding molecules

#22 | 2011-10-20

US20110257601A1

Chemistry; metallurgy

VEGF antagonist formulations for intravitreal administration

#23 | 2010-06-10

US20100144599A1

Human necessities

VEGF PATHWAY BLOCKADE

#24 | 2010-03-25

US20100075903A1

Chemistry; metallurgy

Lyophilized VEGF antagonist formulations for intravitreal administration

#25 | 2009-12-03

US20090299040A1

Chemistry; metallurgy

Multivalent fibronectin based scaffold domain proteins

#26 | 2007-12-20

US20070293432A1

Chemistry; metallurgy

VEGF antagonist formulations suitable for intravitreal administration

InventorID:

29652 ⎘